Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.36 |
| ▸ | PGK2 | P07205 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2728008 | 0.90 | PGK1 (0.38) | PGK1PGK2ALDH1A1L3MBTL1PTPN1 | |
| Trifluoroacetic Acid SCHEMBL28656139 | 0.84 | PGK1 (0.35) | PGK1PGK2ALDH1A1L3MBTL1PTPN1 | |
| Trifluoroacetic Acid SCHEMBL28679728 | 0.84 | ALDH1A1 (0.35) | PGK1PGK2ALDH1A1L3MBTL1PTPN1 | |
| Trifluoroacetic Acid SCHEMBL30657022 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL2484766 | 0.82 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1THRBTSHRMEN1 | |
| Trifluoroacetic Acid SCHEMBL7814389 | 0.82 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1THRBTSHRMEN1 | |
| Trifluoroacetic Acid SCHEMBL474 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL4598430 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL28463674 | 0.81 | SLC34A1 (0.44) | PGK1PGK2ALDH1A1L3MBTL1PTPN1 | |
| SCHEMBL2215889 | 0.79 | THRB (0.46) | PGK1PGK2ALDH1A1L3MBTL1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | claimed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | claimed |
| EP-3757096-A1 | REDOXINDICATORS | Roche Diagnostics GmbH (DE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3183246-B1 | REDOXINDICATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3414239-A2 | INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 | Denali Therapeutics Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10060907-B2 | Redoxindicators | ROCHE DIAGNOSTIC OPERATIONS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170191990-A1 | Redoxindicators | ROCHE DIAGNOSTICS GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | disclosed |
| EP-2132186-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | Novartis AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107436-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170191990-A1 | Redoxindicators | NQO1, SQOR, TST | PGK1 3162/4885PGK2 2382/4885ALDH1A1 172/4885 |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | CYP3A4, CYP2C19, CYP3A43 | PGK1 534/4885PGK2 1074/4885ALDH1A1 1319/4885 |
| US-10060907-B2 | Redoxindicators | NQO1, SQOR, TST | PGK1 3162/4885PGK2 2382/4885ALDH1A1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.